Guardian Pharmacy Services, Inc. (GRDN) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Company: Guardian Pharmacy Services, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: A leading pharmacy services provider for long-term health care facilities (LTCFs), specializing in assisted living and behavioral health facilities. As of June 30, 2025, the company operated 52 pharmacies serving approximately 195,000 residents across 38 states.
Corporate Status: The company completed its IPO in September 2024 and a subsequent follow-on offering in May 2025. It is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | 2025 (YTD) | 2024 (YTD) | Change |
|---|---|---|---|
| Revenue | $673.6 million | $575.4 million | +17.1% |
| Gross Profit | $132.5 million | $116.4 million | +13.8% |
| Gross Margin | 19.7% | 20.2% | -50 bps |
| Operating Income | $25.6 million | $24.9 million | +2.6% |
| Net Income | $18.1 million | $22.9 million | -20.9% |
| Net Income Attributable to Company | $18.5 million | $0 (Pre-IPO) | N/A |
| Diluted EPS | $0.29 | N/A | N/A |
| Adjusted EBITDA | $48.4 million | $41.9 million | +15.5% |
| Cash & Equivalents | $18.8 million | $1.5 million (End of Period) | +1,133% |
| Operating Cash Flow | $37.5 million | $37.8 million | -0.8% |
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 17.1% year-over-year increase, attributed to $30.1 million from acquisitions and $68.1 million from organic growth. Resident count grew from 174,000 to 195,000.
- Profitability Pressure: While operating income increased slightly, Net Income decreased by 20.9% primarily due to the onset of corporate income tax liabilities following the IPO (effective tax rate of 29.6% vs. 0% in the prior period) and increased share-based compensation.
- Expense Increases: SG&A expenses rose 16.9% to $106.9 million, driven by higher employee headcount ($12.8 million) and increased share-based compensation ($2.7 million).
- Interest Expense: Decreased significantly by 81.3% to $0.3 million due to having no outstanding balances on the Credit Facility during the period.
- Liquidity: Cash and cash equivalents increased to $18.8 million from $4.7 million at year-end 2024, bolstered by operating cash flows and the May 2025 follow-on offering proceeds used for share repurchases.
Guidance, Outlook, and Risks
Management Commentary: Management emphasizes a core growth strategy combining organic expansion and acquisitions. The company views the assisted living and behavioral health sectors as the highest growth areas within the LTCF market. The follow-on offering in May 2025 was utilized to repurchase shares issued upon the conversion of Class B stock, resulting in no net change to outstanding Class A shares.
Risks and Contingencies:
- Regulatory & Reimbursement: Risks associated with government efforts to lower pharmaceutical costs and limit pharmacy reimbursements.
- Legal Proceedings: The company faces ordinary course litigation; legal expenses were $2.3 million for the six months ended June 30, 2025.
- Contingent Consideration: Outstanding contingent consideration for acquisitions totaled $2.45 million as of June 30, 2025.
- Tax Legislation: The company is assessing the impact of the "One Big Beautiful Bill Act" (H.R. 1) enacted in July 2025 on its financial statements.
Investor Verification Checklist
- Tax Impact: Verify the sustainability of the ~30% effective tax rate post-IPO and the impact of new tax legislation (H.R. 1).
- Share-Based Compensation: Monitor the trajectory of share-based compensation expenses, which increased significantly ($8.4 million YTD 2025 vs. $5.7 million YTD 2024) and impact net income.
- Acquisition Integration: Assess the contribution of recent acquisitions ($11.1 million total consideration in Q2 2025) to future organic growth and margin expansion.
- Liquidity Position: Confirm the utilization of the $40 million available line of credit and the sufficiency of cash reserves for future capital expenditures and working capital needs.
- Non-GAAP Reconciliations: Review the reconciliation of Adjusted EBITDA ($48.4 million) to Net Income ($18.1 million) to understand the magnitude of non-cash and one-time adjustments.